COPDHFNC COPDNCT07850856
HFNC During Bronchoscopy in COPD Patients
A study testing group N used traditional nasal cannula for oxygen inhalation and Group HFNC used nasal high-flow oxygen inhalation. in people with COPD, run by The First Affiliated Hospital of Guangzhou Medical University.
Trial summary
Bronchoscopy diagnosis and treatment is highly irritating, and the effect of local topical anesthesia is poor; the airway is shared; and COPD patients have low oxygen reserves due to impaired lung function. At present, clinical anesthesia generally uses nasal cannula for oxygen inhalation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COPD
- What is being tested?
- group N used traditional nasal cannula for oxygen inhalation and Group HFNC used nasal high-flow oxygen inhalation.
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 31 Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- COPD ,（ASA）Ⅰ ～ Ⅲ
Who cannot join
- Contraindications to bronchoscopy or anesthesia, Nosebleeds
About this study
Official title: Clinical Study of High-Flow Nasal Cannula Oxygen Support During Bronchoscopy in COPD Patients
Bronchoscopy diagnosis and treatment is highly irritating, and the effect of local topical anesthesia is poor; the airway is shared; and COPD patients have low oxygen reserves due to impaired lung function. At present, clinical anesthesia generally uses nasal cannula for oxygen inhalation. If the anesthesia is too shallow, it may cause airway spasm, and if the anesthesia is too deep, it will inhibit breathing and lead to hypoxia. Hypoxemia has been reported in 66% of COPD patients undergoing sedation for bronchoscopy. Therefore, solving hypoxia is the biggest problem in anesthesia for bronchoscopy diagnosis and treatment.
Read the detailed description
Bronchoscopy diagnosis and treatment is highly irritating, and local topical anesthesia has poor effect; deep sedation or intravenous anesthesia based on topical anesthesia is currently recommended; COPD patients have impaired lung function, and bronchoscopy diagnosis and treatment is accompanied by significant peri-anesthetic risks of hypoxemia. COPD patients are prone to hypoxemia due to the shared airway and sedative and analgesic drugs used to suppress breathing during bronchoscopy diagnosis and treatment. Therefore, solving hypoxia is the biggest problem for COPD patients during anesthesia during bronchoscopy. In recent years, studies have found that high-flow nasal oxygen therapy (HFNC) can significantly reduce the incidence of hypoxemia during anesthesia during bronchoscopy. However, very few studies have performed HFNC on patients with COPD.
- Conditions
- COPD
- Being tested
- group N used traditional nasal cannula for oxygen inhalation, Group HFNC used nasal high-flow oxygen inhalation.
- Keywords
- HFNC, COPD
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
group N used traditional nasal cannula for oxygen inhalationOther
1000 COPD patients who underwent bronchoscopy were randomly divided into 2 groups in a 1:1 ratio.Nasal high-flow oxygen therapy group（group N） and nasal cannula oxygen inhalation group(group HFNC）.The N group used traditional nasal cannula for oxygen inhalation, and the HFNC group used nasal high-flow oxygen inhalation.
Group HFNC used nasal high-flow oxygen inhalation.Other
1000 COPD patients who underwent bronchoscopy were randomly divided into 2 groups in a 1:1 ratio.Nasal high-flow oxygen therapy group（group N） and nasal cannula oxygen inhalation group(group HFNC）.The N group used traditional nasal cannula for oxygen inhalation, and the HFNC group used nasal high-flow oxygen inhalation.
| Study group | Role | What they receive |
|---|---|---|
| Group N | Other | Group N used traditional nasal cannula to inhale oxygen during anesthesia. Receives: Other: group N used traditional nasal cannula for oxygen inhalation |
| Group HFNC | Experimental | During anesthesia, the HFNC group used nasal high-flow oxygen inhalation Receives: Other: Group HFNC used nasal high-flow oxygen inhalation. |
What is being measured
The primary outcome is the main question the study is designed to answer.
pulse oximetry
Blood oxygen saturation during anesthesia, record the duration and number of times below 90%
Measured: The entire anesthesia period during bronchoscopy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2026
- Study start1 Sep 2026 (estimated)
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COPDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study compared the effects of nasal cannula oxygen inhalation and high-flow nasal oxygen therapy (HFNC) on bronchoscopy under anesthesia in COPD patients.
- Masking
- None (open label)
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Liya Lu, The First Affiliated Hospital of Guangzhou Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07850856
- Sponsor's protocol ID
- FAHGuangzhou20260822
- Acronym
- HFNC COPD
- Status last verified
- Sep 2026
- First submitted
- 22 Aug 2026
- Last updated
- 30 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Upon completion of the study, de-identified individual participant data (IPD) and relevant supporting documents (e.g., study protocol, statistical analysis plan) will be shared upon reasonable request with researchers who provide a methodologically sound research proposal. Data will be made available starting 6 months after publication of the primary results and will remain available for 5 years. Requests must be submitted via \[designated email or website\], and a data use agreement must be signed.
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study of High-Flow Nasal Cannula Oxygen Support During Bronchoscopy in COPD Patients
- ClinicalTrials.gov ID
- NCT07850856
- Acronym / sponsor ID
- HFNC COPD / FAHGuangzhou20260822
- Conditions
- COPD
- Keywords
- HFNC, COPD
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical UniversityUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 30 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Bronchoscopy diagnosis and treatment is highly irritating, and the effect of local topical anesthesia is poor; the airway is shared; and COPD patients have low oxygen reserves due to impaired lung function. At present, clinical anesthesia generally uses nasal cannula for oxygen inhalation. If the anesthesia is too shallow, it may cause airway spasm, and if the anesthesia is too deep, it will inhibit breathing and lead to hypoxia. Hypoxemia has been reported in 66% of COPD patients undergoing sedation for bronchoscopy. Therefore, solving hypoxia is the biggest problem in anesthesia for bronchoscopy diagnosis and treatment.
Detailed description
Bronchoscopy diagnosis and treatment is highly irritating, and local topical anesthesia has poor effect; deep sedation or intravenous anesthesia based on topical anesthesia is currently recommended; COPD patients have impaired lung function, and bronchoscopy diagnosis and treatment is accompanied by significant peri-anesthetic risks of hypoxemia. COPD patients are prone to hypoxemia due to the shared airway and sedative and analgesic drugs used to suppress breathing during bronchoscopy diagnosis and treatment. Therefore, solving hypoxia is the biggest problem for COPD patients during anesthesia during bronchoscopy. In recent years, studies have found that high-flow nasal oxygen therapy (HFNC) can significantly reduce the incidence of hypoxemia during anesthesia during bronchoscopy. However, very few studies have performed HFNC on patients with COPD.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study compared the effects of nasal cannula oxygen inhalation and high-flow nasal oxygen therapy (HFNC) on bronchoscopy under anesthesia in COPD patients.
| Arm | Type | Receives |
|---|---|---|
| Group N | Other | Other: group N used traditional nasal cannula for oxygen inhalationGroup N used traditional nasal cannula to inhale oxygen during anesthesia. |
| Group HFNC | Experimental | Other: Group HFNC used nasal high-flow oxygen inhalation.During anesthesia, the HFNC group used nasal high-flow oxygen inhalation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- COPD ,（ASA）Ⅰ ～ Ⅲ
Key exclusion criteria (1 listed)
- Contraindications to bronchoscopy or anesthesia, Nosebleeds
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| group N used traditional nasal cannula for oxygen inhalation1000 COPD patients who underwent bronchoscopy were randomly divided into 2 groups in a 1:1 ratio.Nasal high-flow oxygen therapy group（group N） and nasal cannula oxygen inhalation group(group HFNC）.The N group used traditional nasal cannula for oxygen inhalation, and the HFNC group used nasal high-flow oxygen inhalation. | Other | Group N |
| Group HFNC used nasal high-flow oxygen inhalation.1000 COPD patients who underwent bronchoscopy were randomly divided into 2 groups in a 1:1 ratio.Nasal high-flow oxygen therapy group（group N） and nasal cannula oxygen inhalation group(group HFNC）.The N group used traditional nasal cannula for oxygen inhalation, and the HFNC group used nasal high-flow oxygen inhalation. | Other | Group HFNC |
Primary outcome
pulse oximetry
Time frame: The entire anesthesia period during bronchoscopy
Blood oxygen saturation during anesthesia, record the duration and number of times below 90%
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2026.
- Individual participant dataSharing planned: Yes. Upon completion of the study, de-identified individual participant data (IPD) and relevant supporting documents (e.g., study protocol, statistical analysis plan) will be shared upon reasonable request with researchers who provide a methodologically sound research proposal. Data will be made available starting 6 months after publication of the primary results and will remain available for 5 years. Requests must be submitted via [designated email or website], and a data use agreement must be signed.
Related trials for COPD
Recruiting
Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
Not yet recruitingPhase 2
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Not yet recruitingPhase 3
Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)
Chronic Obstructive Pulmonary Disease
RecruitingObservational study
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Chronic Obstructive Pulmonary Disease (COPD), Smoking
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing group N used traditional nasal cannula for oxygen inhalation and Group HFNC used nasal high-flow oxygen inhalation. in people with COPD, run by The First Affiliated Hospital of Guangzhou Medical University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
pulse oximetry (time frame: The entire anesthesia period during bronchoscopy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.